Proteomics International is a pioneering medical technology company specializing in predictive diagnostics and bioanalytical services. Leveraging advanced proteomics technology, the company develops innovative diagnostic tests that can predict and detect various medical conditions, including diabetic kidney disease, esophageal cancer, and endometriosis. Their groundbreaking approach focuses on creating non-invasive blood tests that offer high accuracy and early detection capabilities.
The company’s flagship products include PromarkerD (a predictive test for diabetic kidney disease), PromarkerEso (a non-invasive esophageal cancer diagnostic), and PromarkerEndo (an endometriosis blood test). These diagnostics represent significant advancements in medical screening, providing healthcare professionals with precise tools to identify potential health risks earlier than traditional methods. Proteomics International has gained international recognition, with their research and tests being featured in prominent medical publications and conferences.
Operationally based in Australia, Proteomics International has expanded its reach internationally, particularly in the United States, where they have launched diagnostic services and participated in major medical conferences. The company combines cutting-edge scientific research with practical medical applications, offering both diagnostic services and analytical services to the healthcare and research communities. Their commitment to innovation is further demonstrated by their ongoing clinical research, strategic collaborations, and continuous development of advanced diagnostic technologies.
Proteomics International (ASX:PIQ) Secures $500,000 Grant to Advance PromarkerEndo Commercialisation Proteomics International Laboratories (ASX:PIQ) has
Join +20,000 subscribers receiving alerts.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
